{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:01:38Z","timestamp":1793314898870,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.critrevonc.2024.104540","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:51:40Z","timestamp":1730397100000},"page":"104540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review"],"prefix":"10.1016","volume":"205","author":[{"given":"Alessandro","family":"Nepote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bertaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Carnio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Piumatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Cantale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino Carmelo","family":"Tralongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104540_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2024.104540_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.lungcan.2013.02.004","article-title":"CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives","volume":"80","author":"Berger","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib4","doi-asserted-by":"crossref","first-page":"S1306","DOI":"10.1016\/j.annonc.2023.10.062","article-title":"Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial","volume":"34","author":"Cho","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib5","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1111\/1759-7714.14169","article-title":"Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: appropriate timing and technique","volume":"12","author":"Gu","year":"2021","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ctrv.2015.05.005","article-title":"Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: a systematic review","volume":"41","author":"Hendriks","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2024.104540_bib8","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from \u3008www.training.cochrane.org\/handbook\u3009., n.d."},{"key":"10.1016\/j.critrevonc.2024.104540_bib9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/cam4.673","article-title":"Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis","volume":"5","author":"Jiang","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2024.104540_bib10","doi-asserted-by":"crossref","first-page":"16725","DOI":"10.18632\/oncotarget.4264","article-title":"Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases","volume":"6","author":"Luo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2024.104540_bib11","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of Brain Metastases in Tyrosine Kinase Inhibitor\u2013Na\u00efve Epidermal Growth Factor Receptor\u2013Mutant Non\u2013Small-Cell Lung Cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772789","article-title":"Modern radiation therapy for the management of brain metastases from non-small cell lung cancer: current approaches and future directions","volume":"11","author":"Mantovani","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.critrevonc.2024.104540_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-023-05538-9","article-title":"Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with\/without upfront LT","volume":"150","author":"Niu","year":"2024","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2024.104540_bib16","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med"},{"key":"10.1016\/j.critrevonc.2024.104540_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104540_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib19","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS Response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib21","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.critrevonc.2024.104540_bib22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104540_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2014.12.011","article-title":"EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis","volume":"114","author":"Soon","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104540_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107540","article-title":"Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-mutant non-small cell lung cancer","volume":"191","author":"Tozuka","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib28","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/annonc\/mdx481","article-title":"Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead","volume":"28","author":"Ulahannan","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib29","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104540_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1634\/theoncologist.2018-0264","article-title":"Osimertinib for EGFR -mutant lung cancer with brain metastases: results from a single-center retrospective study","volume":"24","author":"Xie","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2024.104540_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.05.125","article-title":"Clinical value of upfront cranial radiation therapy in osimertinib-treated epidermal growth factor receptor\u2013mutant non-small cell lung cancer with brain metastases","volume":"111","author":"Yu","year":"2021","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104540_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01955-7","article-title":"Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study","volume":"16","author":"Zhai","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104540_bib33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ijc.33904","article-title":"Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis","volume":"150","author":"Zhao","year":"2022","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/1759-7714.14299","article-title":"Efficacy and safety of WBRT + EGFR-TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: an updated meta-analysis","volume":"13","author":"Zhou","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104540_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1259880","article-title":"The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases","volume":"13","author":"Zhou","year":"2024","journal-title":"Front Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282400283X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282400283X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:22:07Z","timestamp":1734405727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282400283X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"alternative-id":["S104084282400283X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104540","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104540"}}